IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer M Gyrd-Hansen, P Meier Nature Reviews Cancer 10 (8), 561-574, 2010 | 945 | 2010 |
Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization J Nylandsted, M Gyrd-Hansen, A Danielewicz, N Fehrenbacher, ... The Journal of experimental medicine 200 (4), 425-435, 2004 | 686 | 2004 |
OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin K Keusekotten, PR Elliott, L Glockner, BK Fiil, RB Damgaard, Y Kulathu, ... Cell 153 (6), 1312-1326, 2013 | 473 | 2013 |
The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity RB Damgaard, U Nachbur, M Yabal, WWL Wong, BK Fiil, M Kastirr, ... Molecular cell 46 (6), 746-758, 2012 | 404 | 2012 |
Attenuation of c GAS‐STING signaling is mediated by a p62/SQSTM 1‐dependent autophagy pathway activated by TBK1 T Prabakaran, C Bodda, C Krapp, B Zhang, MH Christensen, C Sun, ... The EMBO journal 37 (8), e97858, 2018 | 338 | 2018 |
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis M Gyrd-Hansen, M Darding, M Miasari, MM Santoro, L Zender, W Xue, ... Nature cell biology 10 (11), 1309-1317, 2008 | 320 | 2008 |
OTULIN restricts Met1-linked ubiquitination to control innate immune signaling BK Fiil, RB Damgaard, SA Wagner, K Keusekotten, M Fritsch, ... Molecular cell 50 (6), 818-830, 2013 | 265 | 2013 |
XIAP restricts TNF-and RIP3-dependent cell death and inflammasome activation M Yabal, N Müller, H Adler, N Knies, CJ Groß, RB Damgaard, ... Cell reports 7 (6), 1796-1808, 2014 | 258 | 2014 |
Molecular basis and regulation of OTULIN-LUBAC interaction PR Elliott, SV Nielsen, P Marco-Casanova, BK Fiil, K Keusekotten, ... Molecular cell 54 (3), 335-348, 2014 | 195 | 2014 |
X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis C Speckmann, K Lehmberg, MH Albert, RB Damgaard, M Fritsch, ... Clinical immunology 149 (1), 133-141, 2013 | 182 | 2013 |
Sensitization to the lysosomal cell death pathway upon immortalization and transformation N Fehrenbacher, M Gyrd-Hansen, B Poulsen, U Felbor, T Kallunki, ... Cancer research 64 (15), 5301-5310, 2004 | 178 | 2004 |
SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling PR Elliott, D Leske, M Hrdinka, K Bagola, BK Fiil, SH McLaughlin, ... Molecular cell 63 (6), 990-1005, 2016 | 157 | 2016 |
Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity M Gyrd-Hansen, J Nylandsted, M Jäättelä Cell Cycle 3 (12), 1484-1485, 2004 | 157 | 2004 |
CYLD limits Lys63-and Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling M Hrdinka, BK Fiil, M Zucca, D Leske, K Bagola, M Yabal, PR Elliott, ... Cell reports 14 (12), 2846-2858, 2016 | 153 | 2016 |
Disease‐causing mutations in the XIAP BIR 2 domain impair NOD 2‐dependent immune signalling RB Damgaard, BK Fiil, C Speckmann, M Yabal, U Stadt, S Bekker‐Jensen, ... EMBO molecular medicine 5 (8), 1278-1295, 2013 | 150 | 2013 |
Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease T Schwerd, S Pandey, HT Yang, K Bagola, E Jameson, J Jung, ... Gut 66 (6), 1060-1073, 2017 | 146 | 2017 |
Apoptosome-independent activation of the lysosomal cell death pathway by caspase-9 M Gyrd-Hansen, T Farkas, N Fehrenbacher, L Bastholm, M Høyer-Hansen, ... Molecular and cellular biology 26 (21), 7880-7891, 2006 | 130 | 2006 |
The Met1-linked ubiquitin machinery: emerging themes of (De) regulation M Hrdinka, M Gyrd-Hansen Molecular cell 68 (2), 265-280, 2017 | 127 | 2017 |
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production U Nachbur, CA Stafford, A Bankovacki, Y Zhan, LM Lindqvist, BK Fiil, ... Nature communications 6 (1), 6442, 2015 | 124 | 2015 |
Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors P Canning, Q Ruan, T Schwerd, M Hrdinka, JL Maki, D Saleh, ... Chemistry & biology 22 (9), 1174-1184, 2015 | 109 | 2015 |